Physician profile
Jerry Joseph
NPI 1467869727
$6,978.11
in general payments reported to CMS, 2019-2025
24 companies · $2,643 in 2025
The $2,643 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $100 · 2021: $163 · 2022: $763 · 2023: $1,444 · 2024: $1,865 · 2025: $2,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,929 · Education: $23.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,928.51 |
| Education | $23.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,372.62 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $985.52 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $927.59 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $700.62 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $441.46 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $410.45 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $346.53 | 2022-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $249.05 | 2021-2025 | |
| Lundbeck LLC | $239.95 | 2022-2025 | Rexulti, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $213.09 | 2024-2025 | Cobenfy |
| Indivior INC. | $146.85 | 2022-2025 | Sublocade, Perseris |
| Sunovion Pharmaceuticals INC. | $132.09 | 2021-2022 | |
| Braeburn INC. | $128.42 | 2023-2025 | Brixadi |
| Allergan, INC. | $100.00 | 2020 | |
| Almatica Pharma LLC | $94.08 | 2024-2025 | Loreev Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $92.96 | 2025 | Erzofri Extended-Release |
| Ironshore Pharmaceuticals INC. | $85.99 | 2023-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $79.31 | 2024-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $77.23 | 2025 | Qelbree |
| Idorsia Pharmaceuticals US INC | $48.49 | 2023-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $29.17 | 2023 | Trintellix |
| Invivyd INC | $27.82 | 2025 | Pemgarda |
| Corium, LLC | $27.80 | 2022-2025 | Azstarys |
| Gilead Sciences, INC. | $21.02 | 2023 | Epclusa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.